Aging, Cerebral Amyloid Angiopathy, and Amyloid Beta Clearance
Principal Investigator
Jorge Ghiso, PhD
New York University Grossman School of Medicine
New York, NY, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$250,000
Active Dates
July 01, 2015 - June 30, 2019
Grant ID
A2015275S
Acknowledgement
Co-Principal Investigator(s)
Agueda Rostagno, PhD, New York University Grossman School of Medicine
Goals
Alzheimer’s disease, the most common form of dementia, is characterized by fibrillar deposits of amyloid beta (Aβ) protein in brain tissue and cerebral blood vessels. The complex molecular mechanisms involved in the formation and accumulation of these deposits are not well understood; however, the brain’s failure to remove Aβ is increasingly recognized as a central element in the disease pathogenesis. Our preliminary data indicate that the action of brain enzymes and impaired clearance of the resulting degradation fragments via the blood and cerebrospinal fluid should not be overlooked as crucial contributors. The central focus of this project is how brain Aβ removal is additionally influenced by aging and by the dysfunction of the cerebral microvasculature. Using state of the art methodologies and genetically engineered mouse models with severely compromised cerebral blood vessels, this project will provide a better understanding how the brain degrades and removes Aβ in health and disease, an approach that will likely identify new targets for pharmacologic intervention.
Summary
Grantee institution at the time of this grant: NYU Langone Health
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD